Previous studies using similar doses as those reported here have indeed observed a therapeutic benefit of 5HT1A agonists in cell culture [8,19], models of traumatic brain injury [17], and permanent occlusion models of ischaemia [9,20-23]. Here, HTR1A is linked to brain injury.